Aripiprazole Solution
Product Images NDC 66689-735

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 66689-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vistapharm, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Molecular Formula (Aripiprazole 1)

Chemical structure of aripiprazole, showing the molecular composition with chlorine atoms, nitrogen atoms in piperazine and quinolinone rings, and ether linkage. The image illustrates the detailed atomic arrangement of the aripiprazole molecule.*

FDA Label Image

Figure 9 (Aripiprazole 10)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Abilify Low, Abilify High, and Placebo. The y-axis shows the least-squares mean change in YGTSS total tic score, ranging from 0 to -20, while the x-axis shows weeks of treatment from 0 to 8. All groups show a decrease in tic score, with Abilify High showing the greatest reduction, followed by Abilify Low, and Placebo showing the least change.*

FDA Label Image

Vistapharm Logo (Aripiprazole 11)

FDA Label Image

Aripiprazole Carton (Aripiprazole 12)

Aripiprazole Oral Solution 1 mg per mL carton label with a 150 mL quantity, labeled by VistaPharm, LLC. The packaging includes dosage instructions, storage conditions, and pharmacist dispensing instructions, with the product NDC 66689-735-05 visible on the label.*

FDA Label Image

Aripiprazole Bottle Label (Aripiprazole 13)

Aripiprazole Oral Solution 1 mg per mL in a 150 mL bottle, labeled for prescription use by VistaPharm, Inc. The label includes NDC 66689-735-05, dosing instructions to use the enclosed dosing cup, storage conditions (20° to 25°C with allowed excursions), and a pharmacist reminder to dispense the Medication Guide. Contact information and an unvarnished area for lot number and expiration date are also shown.*

FDA Label Image

Figure 1 (Aripiprazole 2)

A pharmacokinetic (PK) graph showing Aripiprazole fold change with 90% confidence intervals (CI) in the presence of various interacting drugs. The x-axis represents change relative to reference without interacting drug. The chart lists CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam), with their effects on Aripiprazole AUC and Cmax values.*

FDA Label Image

Figure 2 (Aripiprazole 3)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold change in AUC and Cmax relative to reference without interacting drug. It compares effects of CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, lorazepam. Error bars represent 90% confidence intervals for each drug interaction.*

FDA Label Image

Figure 3 (Aripiprazole 4)

A scatter plot chart showing fold change and 90% confidence intervals for various pharmacokinetic (PK) parameters related to CYP2D6, CYP2C9, 2C19, UGT1A4, and other drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents change relative to a reference without an interacting drug, ranging from 0.5 to 3.0.*

FDA Label Image

Figure 4 (Aripiprazole 5)

A pharmacokinetic chart illustrating Aripiprazole fold change with 90% confidence intervals for various special populations. It compares parameters including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment on AUC and Cmax values relative to a reference.*

FDA Label Image

Figure 5 (Aripiprazole 6)

A chart titled "Dehydro-Aripiprazole Fold Change and 90% CI" showing pharmacokinetic data (AUC and Cmax) for Aripiprazole with various factors such as CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference, illustrating differences in exposure and peak concentration under different physiological conditions.*

FDA Label Image

Figure 6 (Aripiprazole 7)

A line graph showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The X-axis represents days from randomization and the Y-axis represents the proportion with relapse. The graph includes a legend differentiating the Aripiprazole group (solid blue line) from the placebo group (dashed red line) and displays the number of subjects at risk for each group at various time points along the X-axis.*

FDA Label Image

Figure 7 (Aripiprazole 8)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole (solid blue line) to placebo (dashed red line). The graph includes the number of subjects at risk at various time points below the x-axis and plots relapse proportions on the y-axis ranging from 0 to 1.*

FDA Label Image

Figure 8 (Aripiprazole 9)

A line chart comparing the proportion of subjects with relapse over 364 days following randomization for Aripiprazole versus placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two lines depict relapse trends: a solid blue line for Aripiprazole and a dashed red line for placebo. Below the x-axis, the number of subjects at risk is shown for each group across different time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.